Northland Capital Reaffirms Motif Bio Plc (LON:MTFB)’s Buy Rating; ARGOS THERAPEUTICS Has 0.85 Sentiment

In analysts note revealed to investors on Tuesday, 20 March, Motif Bio Plc (LON:MTFB) stock had its Buy Rating reconfirmed by research professionals at Northland Capital.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $7.67 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

The stock decreased 6.96% or GBX 2.4742 during the last trading session, reaching GBX 33.0758. About 972,667 shares traded or 47.15% up from the average. Motif Bio plc (LON:MTFB) has 0.00% since March 20, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Motif Bio plc (LON:MTFB) to report earnings on May, 7.

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company has market cap of 87.41 million GBP. The firm develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. It currently has negative earnings. The Company’s lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.

Among 4 analysts covering Motif Bio Plc (LON:MTFB), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Motif Bio Plc has GBX 140 highest and GBX 90 lowest target. GBX 101.50’s average target is 206.87% above currents GBX 33.0758 stock price. Motif Bio Plc had 87 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, March 20 by Peel Hunt. Northland Capital maintained it with “Buy” rating and GBX 114 target in Wednesday, April 20 report. Beaufort Securities maintained Motif Bio plc (LON:MTFB) rating on Monday, June 5. Beaufort Securities has “Speculative Buy” rating and GBX 110 target. The stock of Motif Bio plc (LON:MTFB) has “Speculative Buy” rating given on Tuesday, January 26 by Beaufort Securities. The company was maintained on Tuesday, May 30 by FinnCap. Northland Capital maintained Motif Bio plc (LON:MTFB) rating on Thursday, August 27. Northland Capital has “Buy” rating and GBX 114 target. The stock has “Speculative Buy” rating by Beaufort Securities on Thursday, April 21. The firm earned “Buy” rating on Tuesday, September 29 by Northland Capital. Northland Capital maintained the shares of MTFB in report on Wednesday, November 15 with “Buy” rating. Northland Capital maintained it with “Buy” rating and GBX 114 target in Monday, August 24 report.

The stock increased 0.81% or $0.01 during the last trading session, reaching $1.25. About 546,117 shares traded. Argos Therapeutics, Inc. (ARGS) has declined 92.57% since March 20, 2017 and is downtrending. It has underperformed by 109.27% the S&P500.

Ratings analysis reveals 0 of Argos Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Argos Therapeutics, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ARGS was included in 2 notes of analysts from February 22, 2017. The rating was downgraded by FBR Capital to “Mkt Perform” on Wednesday, February 22. The firm earned “Mkt Perform” rating on Wednesday, February 22 by JMP Securities.